Stock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products

Stock Track

2024/11/01

Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.

The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.

CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1170856402"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170856402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170856402?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170856402","market":"hk","top_or_hot":-1,"title":"Stock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products","media":"Stock Track","content":"<p>Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.</p>\n\n<p>The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.</p>\n\n<p>CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-01 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.</p>\n\n<p>The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.</p>\n\n<p>CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1170856402","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170856402","pubTimestamp":1730424781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CARsgen Therapeutics Holdings Ltd  surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration  has lifted clinical holds on three of its investigational products.The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"随着FDA解除关键产品的临床限制，科济生物股价飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.\nThe FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.\nCARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}